Search Results - "Caramazza, Domenica"

Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study by TEFFERI, Ayalew, VAIDYA, Rakhee, CARAMAZZA, Domenica, FINKE, Christy, LASHO, Terra, PARDANANI, Animesh

“…Abnormal cytokine expression accompanies myelofibrosis and might be a therapeutic target for Janus-associated kinase (JAK) inhibitor drugs. This study…”
Get full text

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status by GANGAT, Naseema, CARAMAZZA, Domenica, CERVANTES, Francisco, PASSAMONTI, Francesco, TEFFERI, Ayalew, VAIDYA, Rakhee, GEORGE, Geeta, BEGNA, Kebede, SCHWAGER, Susan, VAN DYKE, Daniel, HANSON, Curtis, WENTING WU, PARDANANI, Animesh

“…The Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis (PMF) uses five risk factors to predict survival: age older than 65…”
Get full text

JAK Inhibitor in CALR-Mutant Myelofibrosis by Passamonti, Francesco, Caramazza, Domenica, Maffioli, Margherita, Cazzola, Mario, Kralovics, Robert

“…To the Editor: Janus kinase (JAK) inhibitors are new targeted therapies for myelofibrosis that reduce the palpable spleen size to 50% of the baseline…”
Get full text

Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection by Merli, Michele, Ageno, Walter, Sessa, Fausto, Salvini, Marco, Caramazza, Domenica, Mora, Barbara, Rossi, Agostino, Rovelli, Cristina, Passamonti, Francesco, Grossi, Paolo

Get full text

A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment by Passamonti, Francesco, Thiele, Jürgen, Girodon, Francois, Rumi, Elisa, Carobbio, Alessandra, Gisslinger, Heinz, Kvasnicka, Hans Michael, Ruggeri, Marco, Randi, Maria Luigia, Gangat, Naseema, Vannucchi, Alessandro Maria, Gianatti, Andrea, Gisslinger, Bettina, Müllauer, Leonhard, Rodeghiero, Francesco, d'Amore, Emanuele S.G., Bertozzi, Irene, Hanson, Curtis A., Boveri, Emanuela, Marino, Filippo, Maffioli, Margherita, Caramazza, Domenica, Antonioli, Elisabetta, Carrai, Valentina, Buxhofer-Ausch, Veronika, Pascutto, Cristiana, Cazzola, Mario, Barbui, Tiziano, Tefferi, Ayalew

“…Diagnosis of essential thrombocythemia (ET) has been updated in the last World Health Organization (WHO) classification. We developed a prognostic model to…”
Get full text

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts by Passamonti, Francesco, Maffioli, Margherita, Cervantes, Francisco, Vannucchi, Alessandro Maria, Morra, Enrica, Barbui, Tiziano, Caramazza, Domenica, Pieri, Lisa, Rumi, Elisa, Gisslinger, Heinz, Knoops, Laurent, Kiladjian, Jean Jaques, Mora, Barbara, Hollaender, Norbert, Pascutto, Cristiana, Harrison, Claire, Cazzola, Mario

“…The international prognostic scoring system (IPSS) provides reliable risk assessment in patients with primary myelofibrosis (PMF). Recent clinical trials in…”
Get full text

Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers by Cantoni, Silvia, Carpenedo, Monica, Mazzucconi, Maria Gabriella, De Stefano, Valerio, Carrai, Valentina, Ruggeri, Marco, Specchia, Giorgina, Vianelli, Nicola, Pane, Fabrizio, Consoli, Ugo, Artoni, Andrea, Zaja, Francesco, D'adda, Mariella, Visentin, Andrea, Ferrara, Felicetto, Barcellini, Wilma, Caramazza, Domenica, Baldacci, Erminia, Rossi, Elena, Ricco, Alessandra, Ciminello, Angela, Rodeghiero, Francesco, Nichelatti, Michele, Cairoli, Roberto

“…Sequential use of the TPO‐RAs romiplostim and eltrombopag in ITP patients failing either agent was retrospectively evaluated to assess efficacy and impact of…”
Get full text

Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients by Tefferi, Ayalew, Jimma, Thitina, Gangat, Naseema, Vaidya, Rakhee, Begna, Kebede H., Hanson, Curtis A., Van Dyke, Daniel L., Caramazza, Domenica, Pardanani, Animesh

“…DIPSS-plus (the Dynamic International Prognostic Scoring System-plus) includes 8 risk factors for survival in primary myelofibrosis. In the present study of…”
Get full text

Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry by Agosti, Pasquale, De Leo, Pasqualina, Capecchi, Marco, Ferrari, Barbara, Mancini, Ilaria, Gattillo, Salvatore, Trisolini, Silvia Maria, Rinaldi, Erminia, Podda, Gian Marco, Prezioso, Lucia, Salutari, Prassede, Facchini, Luca, Caramazza, Domenica, Tolomelli, Giulia, Artoni, Andrea, Peyvandi, Flora

“…•Data on caplacizumab use for thrombotic thrombocytopenic purpura (TTP) in Italy are missing.•Twenty-six Italian patients were treated with caplacizumab for an…”
Get full text

It is time to change thrombosis risk assessment for PV and ET? by Passamonti, Francesco, MD, Caramazza, Domenica, MD, Mora, Barbara, MD, Casalone, Rosario, MD, Maffioli, Margherita, MD

“…Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms to be diagnosed according to the WHO classification. Molecular…”
Get full text

PB2611: EVANS SYNDROME: DISEASE AWARENESS AND CLINICAL MANAGEMENT IN A NATION‐WIDE ITALIAN SURVEY by Fattizzo, Bruno, Carrai, Valentina, Crugnola, Monica, Baldacci, Erminia, Bellini, Marta, Bosi, Costanza, Buzzatti, Elisa, Caramazza, Domenica, Carli, Giuseppe, Carpenedo, Monica, Clissa, Cristina, Danesin, Cristina, De Paolis, Maria Rosaria, Giannotta, Juri Alessandro, Innao, Vanessa, Marchetti, Monia, Markovic, Uros, Morotti, Alessandro, Napolitano, Mariasanta, Patriarca, Andrea, Pettine, Loredana, Poloni, Antonella, Rivolti, Elena, Rossi, Elena, Santeremo, Teresa Maria, Santoro, Cristina, Zannier, Maria Elena, Zaja, Francesco, Cantoni, Silvia, Palandri, Francesca, Stefano, Valerio De

Get full text

Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab by Caramazza, Domenica, Quintini, Gerlando, Abbene, Ignazio, Malato, Alessandra, Saccullo, Giorgia, Coco, Lucio Lo, Di Trapani, Rosa, Palazzolo, Roberto, Barone, Rita, Mazzola, Giuseppina, Rizzo, Sergio, Ragonese, Paolo, Aridon, Paolo, Abbadessa, Vincenzo, Siragusa, Sergio

“…Idiopathic thrombotic thrombocytopenic purpura–hemolytic uremic syndrome (TTP‐HUS) is a rare disease responsive to treatment with plasma exchange (PE) but with…”
Get full text

Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations by Caramazza, Domenica, Hussein, Kebede, Siragusa, Sergio, Pardanani, Animesh, Knudson, Ryan A., Ketterling, Rhett P., Tefferi, Ayalew

“…Chromosome 1 is the largest human chromosome and contains over 1600 known genes and 1000 novel coding sequences or transcripts. It is, therefore, not…”
Get full text

Clinical Predictors of Outcome in MPN by Passamonti, Francesco, MD, Maffioli, Margherita, MD, Merli, Michele, MD, Ferrario, Andrea, MD, Caramazza, Domenica, MD

“…Myeloproliferative neoplasms include 3 diseases: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). PV and ET are…”
Get full text

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls by Verstovsek, Srdan, Kantarjian, Hagop M., Estrov, Zeev, Cortes, Jorge E., Thomas, Deborah A., Kadia, Tapan, Pierce, Sherry, Jabbour, Elias, Borthakur, Gautham, Rumi, Elisa, Pungolino, Ester, Morra, Enrica, Caramazza, Domenica, Cazzola, Mario, Passamonti, Francesco

“…Ruxolitinib is JAK1/JAK2 inhibitor with established clinical benefit in myelofibrosis (MF). We analyzed long-term outcomes of 107 patients with intermediate-2…”
Get full text

New generation small-molecule inhibitors in myeloproliferative neoplasms by Passamonti, Francesco, Maffioli, Margherita, Caramazza, Domenica

“…PURPOSE OF REVIEWMyeloproliferative neoplasms (MPNs) are diseases that carry the JAK2 (V617F) mutation in about 70% of the patients. The purpose of this review…”
Get full text

Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients by Mora, Barbara, Guglielmelli, Paola, Kuykendall, Andrew, Rumi, Elisa, Maffioli, Margherita, Palandri, Francesca, De Stefano, Valerio, Caramella, Marianna, Salmoiraghi, Silvia, Kiladjian, Jean-Jacques, Gotlib, Jason, Iurlo, Alessandra, Cervantes, Francisco, Ruggeri, Marco, Silver, Richard T., Albano, Francesco, Benevolo, Giulia, Ross, David M., Della Porta, Matteo G., Devos, Timothy, Rotunno, Giada, Komrokji, Rami S., Casetti, Ilaria C., Merli, Michele, Brociner, Marco, Caramazza, Domenica, Auteri, Giuseppe, Barbui, Tiziano, Cattaneo, Daniele, Bertù, Lorenza, Arcaini, Luca, Vannucchi, Alessandro M., Passamonti, Francesco

“…Patients with Philadelphia-negative myeloproliferative neoplasms are at high risk of thrombotic events (TEs). Predisposing factors have been identified in…”
Get full text

Evans syndrome: Disease awareness and clinical management in a nation‐wide ITP‐NET survey by Fattizzo, Bruno, Carrai, Valentina, Crugnola, Monica, Baldacci, Erminia, Bellini, Marta, Bosi, Costanza, Buzzatti, Elisa, Caramazza, Domenica, Carli, Giuseppe, Carpenedo, Monica, Clissa, Cristina, Danesin, Cristina, De Paolis, Maria Rosaria, Giannotta, Juri Alessandro, Innao, Vanessa, Marchetti, Monia, Markovic, Uros, Morotti, Alessandro, Napolitano, Mariasanta, Patriarca, Andrea, Pettine, Loredana, Poloni, Antonella, Rivolti, Elena, Rossi, Elena, Santeremo, Teresa Maria, Santoro, Cristina, Zannier, Maria Elena, Zaja, Francesco, Cantoni, Silvia, Palandri, Francesca, De Stefano, Valerio

“…Evans syndrome (ES) is rare and mostly treated on a “case‐by‐case” basis and no guidelines are available. With the aim of assessing disease awareness and…”
Get full text

Cerebral venous thrombosis and myeloproliferative neoplasms: Results from two large databases by Dentali, Francesco, Ageno, Walter, Rumi, Elisa, Casetti, Ilaria, Poli, Daniela, Scoditti, Umberto, Maffioli, Margherita, di Minno, Matteo Nicola Dario, Caramazza, Domenica, Pietra, Daniela, De Stefano, Valerio, Passamonti, Francesco

“…Abstract Introduction Myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)…”
Get full text

Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies by Passamonti, Francesco, Maffioli, Margherita, Caramazza, Domenica, Cazzola, Mario

“…Most BCR-ABL1-negative myeloproliferative neoplasms (MPN) carry an activating JAK2 mutation. Approximately 96% of patients with polycythemia vera (PV) harbors…”
Get full text